Valuation: Prothena Corporation plc

Market Cap 419M 381M 352M 318M 600M 39.34B 621M 4.23B 1.68B 21.11B 1.57B 1.54B 66.88B P/E 2026 *
-336x
P/E 2027 * -8.03x
Enterprise Value 419M 381M 352M 318M 600M 39.34B 621M 4.23B 1.68B 21.11B 1.57B 1.54B 66.88B EV / Sales 2026 *
5.79x
EV / Sales 2027 * 19.9x
Free-Float
77.56%
Yield 2026 *
-
Yield 2027 * -
1 day-1.41%
1 week-8.89%
Current month-5.61%
1 month-4.25%
3 months-9.97%
6 months-16.63%
Current year-16.28%
1 week 7.86
Extreme 7.86
8.78
1 month 7.79
Extreme 7.7943
9.26
Current year 7.73
Extreme 7.73
11.8
1 year 7.73
Extreme 7.73
11.8
3 years 4.32
Extreme 4.32
41.54
5 years 4.32
Extreme 4.32
79.65
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap. Importance
27/10/26 Don 566,444 1.1034%
23/10/26 Buy 50,000 0.0974%
14/10/26 Buy 10,000 0.0195%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%-8.89%-22.00%-76.82% 419M
-1.29%-1.76%+51.98%+64.66% 66.33B
-0.09%+2.79%+10.75%+95.02% 60.62B
+0.63%+1.64%+24.25%+89.70% 55.5B
-0.96%-1.22%+9.45%+117.91% 47.58B
-0.07%-4.92%+22.68%+29.47% 43.69B
-3.06%-16.63%+141.34%+685.22% 37.27B
+0.23%+1.66%+14.85%+49.06% 36.57B
+2.35%-3.61%+78.64%+60.70% 32.22B
+1.35%+6.10%-37.60%+404.03% 26.58B
Average -0.21%+0.53%+29.43%+151.90% 41B
Weighted average by Cap. -0.22%+0.33%+34.96%+152.22%

Financials

2026 *2027 *
Net sales 72.42M 65.8M 60.79M 54.91M 104M 6.8B 107M 731M 290M 3.65B 272M 266M 11.56B 21.04M 19.11M 17.66M 15.95M 30.1M 1.98B 31.16M 212M 84.14M 1.06B 78.93M 77.26M 3.36B
Net income -1.38M -1.26M -1.16M -1.05M -1.98M -130M -2.05M -13.97M -5.53M -69.71M -5.19M -5.08M -221M -53.67M -48.76M -45.05M -40.69M -76.8M -5.04B -79.5M -542M -215M -2.7B -201M -197M -8.57B
Net Debt - -
Projected Income Statement - Annual - Prothena Corporation plc
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
17/11/26 US$8.005 -1.90% 146,853
13/11/26 US$8.160 -0.85% 340,754
12/11/26 US$8.230 -5.73% 237,031
11/11/26 US$8.730 +1.99% 392,332
10/11/26 US$8.560 -2.45% 394,176
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Prothena Corporation plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
8.160USD
Average target price
21.40USD
Spread / Average Target
+162.25%
  1. Stock Market
  2. Stocks
  3. PRTA Stock